SPC
TCRT icon

Sigma Planning Corp’s Alaunos Therapeutics TCRT Stock Holding History

Sigma Planning Corp’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-487
Closed -$80K – 1490
2021
Q4 		$80K Buy
487
+118
+32% +$25.9K ﹤0.01% 1337
2021
Q3 		$101K Buy
+369
New +$113K ﹤0.01% 1315
2021
Q1 		– Sell
-112
Closed -$42K – 1404
2020
Q4 		$42K Sell
112
-38
-25% -$15.1K ﹤0.01% 1177
2020
Q3 		$57K Buy
150
+32
+27% +$14.1K ﹤0.01% 1037
2020
Q2 		$58K Buy
118
+31
+36% +$13.8K ﹤0.01% 1026
2020
Q1 		$32K Buy
+87
New +$45K ﹤0.01% 891
2019
Q3 		– Sell
-183
Closed -$160K – 1062
2019
Q2 		$160K Buy
+183
New +$126K 0.01% 933

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sigma Planning Corp's TCRT Position: Q1 2022 in Review

Sigma Planning Corp sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 487 shares — an estimated $80K sold.

Sigma Planning Corp first reported a position in TCRT in Q2 2019 and held it in 7 quarters. The position peaked at $160K in Q2 2019. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

  • Sigma Planning Corp reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sigma Planning Corp sold 487 Alaunos Therapeutics shares in Q1 2022, an estimated $80K.
  • Sigma Planning Corp first reported a position in Alaunos Therapeutics in Q2 2019 and held it in 7 quarters.
  • Sigma Planning Corp's Alaunos Therapeutics position peaked at $160K in Q2 2019.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on Sigma Planning Corp's 13F filing for Q1 2022, filed 20 Apr 2022.